Transgene S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNG.PA research report →
About the company
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers.
- CEO
- Alessandro Riva
- IPO
- 2000
- Employees
- 144
- HQ
- Illkirch-Graffenstaden, FR
Price Chart
- Market Cap
- $105.99M
- P/E
- -2.83
- P/S
- 773.63
- P/B
- 0.96
- EV/EBITDA
- -2.55
- Div Yield
- 0.00%
- Gross Margin
- 357.66%
- Op Margin
- -29978.10%
- Net Margin
- -27389.78%
- ROE
- -63.53%
- ROIC
- -27.43%
- Revenue
- $490.00K · -92.29%
- Net Income
- $-37,524,000 · -10.46%
- EPS
- $-0.26 · 10.34%
- Op Income
- $-41,070,000
- FCF YoY
- -41.15%
- 52W High
- $1.50
- 52W Low
- $0.73
- 50D MA
- $0.78
- 200D MA
- $0.95
- Beta
- 0.71
- Avg Volume
- 44.29K
Get TickerSpark's AI analysis on TNG.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TNG.PA coverage
Recent articles, reports, and earnings notes.
No research on TNG.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNG.PA report →Similar companies
Peers in the same neighborhood.